Taurine and proline promote lung tumour growth by co-regulating Azgp1/mTOR signalling pathway
- Tu-Liang Liang 1, Ying Chen 1, Nan-Jie Zhou 1, Xiao Shu 1, Jia-Ning Mi 1, Gang-Yuan Ma 2,3, Yao Xiao 1, Xi Yang 4, Chen Huang 4, Jia-Xin Li 5, Ying Xie 1, Pei-Yu Yan 4, Xiao-Jun Yao 6, Liang Liu 1,3, Hu-Dan Pan 7, Elaine Lai-Han Leung 8, Run-Ze Li 9
- Tu-Liang Liang 1, Ying Chen 1, Nan-Jie Zhou 1
- 1State Key Laboratory of Traditional Chinese Medicine Syndrome/Chinese Medicine, Guangdong Laboratory, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, PR China.
- 2Guangzhou Medical University, Guangzhou, 510182, PR China.
- 3Guangzhou Laboratory, Guangzhou, 510005, PR China.
- 4Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Macau (SAR), PR China.
- 5Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- 6Faculty of Applied Sciences, Macao Polytechnic University, Macao, 999078, China.
- 7State Key Laboratory of Traditional Chinese Medicine Syndrome/Chinese Medicine, Guangdong Laboratory, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, PR China. hdpan@gzucm.edu.cn.
- 8Cancer Center, Faculty of Health Science, MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau (SAR), China. lhleung@um.edu.mo.
- 9State Key Laboratory of Traditional Chinese Medicine Syndrome/Chinese Medicine, Guangdong Laboratory, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, PR China. lirunzetk@163.com.
- 0State Key Laboratory of Traditional Chinese Medicine Syndrome/Chinese Medicine, Guangdong Laboratory, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, PR China.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Taurine and proline promote lung cancer by downregulating Zinc-α2-glycoprotein (Azgp1), impacting lipid metabolism via the mammalian target of rapamycin (mTOR) pathway. Targeting the Azgp1/mTOR axis offers new therapeutic strategies for lung cancer.
Area Of Science
- Oncology
- Metabolomics
- Molecular Biology
Background
- Accurate metabolic biomarkers for lung cancer prognosis are scarce.
- Taurine and proline are consistently elevated in various cancer stages, suggesting a role in disease progression.
Purpose Of The Study
- To elucidate the role of taurine and proline in lung cancer prognosis.
- To identify the molecular mechanisms by which these metabolites influence cancer progression.
Main Methods
- Transcriptomic analysis to identify gene expression changes.
- Investigated the impact of metabolites on gene expression and cellular pathways.
- Utilized gene overexpression to assess effects on cancer progression and signaling pathways.
Main Results
- Taurine and proline were found to downregulate Zinc-α2-glycoprotein (Azgp1).
- Azgp1 influences downstream lipid metabolic pathways in lung cancer.
- Both metabolites affected lipid metabolism via the mammalian target of rapamycin (mTOR) pathway.
- Overexpression of Azgp1 significantly slowed lung cancer progression and reduced mTOR activity.
Conclusions
- Taurine and proline exhibit a pro-cancer role in lung cancer.
- The Azgp1/mTOR axis is a critical pathway in lung cancer progression.
- This pathway represents a potential therapeutic target for lung cancer treatment.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.